Sarepta announced first clinical data from Phase 1/2 studies of SRP-1001 for FSHD1 and SRP-1003 for DM1, showing dose-dependent muscle exposure, early biomarker effects, and favorable tolerability with mostly mild to moderate adverse events.1
The αvβ6 integrin-targeted siRNA platform achieved high muscle concentrations without dose-limiting toxicity, supporting potential for higher dosing and clinical efficacy.1
Following a challenging 2025 marked by patient deaths in Elevidys trials and a pivot to siRNA therapies, Sarepta anticipates catalyst-rich 2026 with more data updates and pivotal studies in 2027.24
Jefferies analysts forecast $1 billion market opportunity for each siRNA program in FSHD and DM1, with potential 25-50% stock movement on positive data.4
Sarepta hosted an investor call on March 25, 2026, to discuss these early results, reinforcing confidence in the siRNA pipeline licensed from Arrowhead Pharmaceuticals.1
Sources:
1. https://www.businesswire.com/news/home/20260325621936/en/Sarepta-Announces-First-Clinical-Data-from-siRNA-Pipeline-Targeting-FSHD1-and-DM1
2. https://www.statnews.com/2026/03/25/sarepta-therapeutics-fshd-dm1-study-results/
4. https://www.biospace.com/business/after-mortality-marred-year-sarepta-looks-ahead-to-catalyst-rich-2026